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Bone remodeling is the continuous process of bone resorption by osteoclasts and bone 
formation by osteoblasts, in order to maintain homeostasis. The activity of osteoclasts 
and osteoblasts is regulated by a network of signaling pathways, including Wnt, para-
thyroid hormone (PTH), RANK ligand/osteoprotegrin, and TGF-β, in response to stimuli, 
such as mechanical loading. During aging there is a gradual loss of bone mass due to 
dysregulation of signaling pathways. This may be due to a decline in physical activity with 
age and/or changes in hormones and other signaling molecules. In particular, hormones, 
such as PTH, have a circadian rhythm, which may be disrupted in aging. Due to the 
complexity of the molecular and cellular networks involved in bone remodeling, sev-
eral mathematical models have been proposed to aid understanding of the processes 
involved. However, to date, there are no models, which explicitly consider the effects 
of mechanical loading, the circadian rhythm of PTH, and the dynamics of signaling 
molecules on bone remodeling. Therefore, we have constructed a network model of the 
system using a modular approach, which will allow further modifications as required in 
future research. The model was used to simulate the effects of mechanical loading and 
also the effects of different interventions, such as continuous or intermittent administra-
tion of PTH. Our model predicts that the absence of regular mechanical loading and/or 
an impaired PTH circadian rhythm leads to a gradual decrease in bone mass over time, 
which can be restored by simulated interventions and that the effectiveness of some 
interventions may depend on their timing.
Keywords: bone remodeling, circadian cycle, cell signaling, mechanical loading, parathyroid hormone, stochastic 
simulation
inTrODUcTiOn
Bone remodeling is the continuous process of bone resorption and formation in order to repair 
micro-fractures and maintain mineral homeostasis. Osteoclasts and osteoblasts work together in 
“basic multicellular units” (BMUs) to resorb and form new bone, respectively. An imbalance in bone 
remodeling occurs in disease, such as Paget’s disease or cancer, and loss of homeostasis may occur 
in aging. In particular, loss of bone mass occurs with age and may lead to osteoporosis. This may be 
due to a decline in the number of osteoblasts with age. Osteoblasts are derived from mesenchymal 
stem cells (MSCs) (1) and are induced to differentiate by activation of the Wnt signaling pathway 
and by growth factors, e.g., BMPs and TGF-β. After osteoblasts have carried out bone formation, 
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they either mature into osteocytes, which are embedded in the 
new bone matrix, form lining cells, or undergo apoptosis.
Osteoclasts are derived from hematopoietic stem cells (HSCs) 
(2). Differentiation of HSCs into progenitor cells requires mac-
rophage colony-stimulating factor (MCSF) (3), which is secreted 
by osteoblasts and MSCs (3). Osteoclast progenitor cells express 
receptor activator of NFκB (RANK) receptors and require the 
RANK ligand (RANKL) for further differentiation into mature 
osteoclasts (Ocl_m) (4). After osteoclasts have carried out the 
resorption process, they undergo apoptosis.
Osteocytes are buried deep in the bone matrix and make up 
>90% of cells in bone. Although it was once thought that these cells 
are quiescent, it is now known that they have an important role in 
maintenance of bone homeostasis, as they respond to mechanical 
stimuli (by receiving signals from integrins) and secrete signaling 
molecules. In the absence of mechanical forces, osteocytes may 
undergo apoptosis (5). This may be due to a decrease in levels of 
nitric oxide (6) or prostaglandin E2 (PGE2) (7).
Many signaling pathways are important in bone remodeling. 
In particular, the RANK–RANKL–OPG pathway plays a major 
role in bone remodeling (8, 9). Osteoprotegrin (OPG) is a decoy 
ligand, which binds to RANKL, thus preventing RANKL binding 
to RANK. Therefore, the RANKL/OPG ratio is very important in 
maintaining bone homeostasis. MSCs, osteoblasts (mature and 
precursor cells), and osteocytes secrete RANKL. It is thought that 
MSCs only express low levels of RANKL. The general consensus 
was that osteoblasts are the main source of RANKL, but there 
has recently been a paradigm shift, and osteocytes are now con-
sidered to be important [e.g., Ref. (10)]. Osteoblasts also secrete 
OPG. It has been suggested that osteoblast precursor cells (Ob_p) 
secrete high levels of RANKL and low levels of OPG, whereas 
the reverse is true for mature osteoblasts (Ob_m) (11), so that 
the RANKL/OPG ratio changes during osteoblast differentiation. 
This would mean that osteoclastogenesis is promoted during 
early differentiation of osteoblasts, but inhibited at later stages.
An important pathway for osteoblastogenesis is TGF-β 
signaling. TGF-β is required for differentiation of MSCs into 
osteoblast precursors, but inhibits later stages of the differentia-
tion process (12). TGF-β is produced and secreted by osteoblasts 
and is abundantly present in the bone matrix in a latent form. It is 
released from the bone matrix by osteoclasts during the process 
of bone resorption (13).
Another important pathway in bone remodeling is canonical 
Wnt signaling. Wnt is known to promote osteoblast proliferation 
and differentiation (14). Osteocytes secrete sclerostin, which 
inhibits Wnt signaling, especially during unloading when they 
are in a quiescent state (15, 16). It has been shown that activa-
tion of Wnt prevents osteocyte apoptosis (14), suggesting that 
apoptosis of osteocytes occurs when they are inactive during 
unloading. Parathyroid hormone (PTH) also leads to activation 
of osteocytes and may compensate for a lack of mechanical stimu-
lation [reviewed in Ref. (17)].
Parathyroid hormone receptors are found on osteoblasts 
and osteocytes. Signaling via PTH leads to an increase in the 
RANKL/OPG ratio due to inhibition of OPG secretion and an 
increase in RANKL secretion from osteoblasts (18), leading to 
more bone resorption. On the other hand, PTH can increase 
bone formation by a number of mechansims. For example, it is 
known to increase Wnt signaling by activating osteocytes and 
so lowering levels of the Wnt inhibitor, sclerostin (19). PTH 
also increases Wnt signaling by changing the expression of 
Wnt signaling components via the cAMP-PKA pathway (20). 
Furthermore, PTH inhibits osteoblast apoptosis, as, when, PTH 
binds to receptors on osteoblasts, a signaling cascade involving 
phosphorylation of CREB is activated (21). Phosphorylated 
CREB binds to Runx2, which leads to the nuclear transloca-
tion and transcriptional activity of Runx2, a key transcription 
factor in bone formation. One of the genes regulated by Runx2 
is Bcl2, which binds to the proapoptotic protein Bax to inhibit 
apoptosis of osteoblasts. PTH also enhances the degradation of 
Runx2, which provides a negative feedback loop to terminate 
transcription of Runx2 genes. PTH has a very short half-life of 
only a few minutes (22), so that it is normally kept at low basal 
levels. It has been suggested that PTH is normally present below 
the threshold required for signaling and that other signaling 
pathways are required, e.g., purinergic signaling (23). Previous 
experiments have shown that continuous administration of 
PTH leads to bone loss, whereas intermittent PTH results 
in bone formation (24–26). Importantly, PTH levels have a 
circadian rhythm in humans, and this rhythm is disturbed in 
postmenopausal women. Joseph et al. (27) showed that elderly 
men and premenopausal women have two peaks of PTH per day 
(a lower peak in late afternoon, followed by a higher nocturnal 
peak), whereas postmenopausal women have a higher sustained 
increase in nocturnal PTH levels without the earlier peak.
Several mathematical models of bone remodeling have been 
published (28–34). Many of these models use ordinary differ-
ential equations to model the differentiation and dynamics of 
osteoblast and osteoclast cells. They include the effects of chemi-
cal species, such as OPG, RANKL, PTH, and TGF-β, but do not 
follow the dynamics of these species, instead representing them 
as parameters in reaction rates. Graham et al. (29) extended pre-
vious models to include the role of osteocytes, sclerostin, and the 
contribution of osteocytes to RANKL secretion. Currently, there 
are few models that include the role of mechanical loading on 
bone remodeling. Scheiner et al. (35) extended previous models 
(32, 33) and were the first to include mechanoregulatory feed-
back mechanisms by combining bone cell population kinetics 
with multiscale bone mechanics. Pivonka et al. (36) developed 
this further to include the bone microstructure in which they 
examined the influence of bone surface availability. However, to 
date, we are not aware of any mathematical model that explicitly 
examines the effect of changes in the circadian rhythm of PTH 
on the different signaling pathways involved in bone remodeling 
or the interplay between periodical mechanical loading and the 
PTH cycle on the system. The aim of this study was to construct 
an integrative computational model of bone remodeling in order 
to examine the effects of loading/unloading, the PTH circadian 
rhythm, and their synergistic effects, if any, on bone homeostasis. 
After establishing which conditions lead to loss of bone mass, 
we used the model to simulate different interventions, such as 
RANKL inhibitors, sclerostin inhibitors, and bisphosphonates, 
in order to try and restore bone homeostasis. In particular, 
since both mechanical loading and PTH have periodical effects 
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over limited time periods, we used the model to investigate the 
question of whether the actual timing of interventions, such as 
administration of PTH or bouts of physical exercise, affect the 
dynamics of bone remodeling.
We also examined the effects of different PTH treatments in 
order to validate our model against experimental data, which 
indicate opposing effects of continuous versus intermittent PTH 
administration [e.g., Ref. (37, 38)]. The reasons for this are not 
fully understood and are likely to be due to a combination of 
mechanisms (39). For example, the increase in bone mass by 
intermittent PTH may be due to downregulation of sclerostin 
(40), leading to an increase in osteoblast number and more bone 
formation. Previous mathematical models have also examined 
the opposing effects of PTH, using different model assumptions. 
For example, Kroll assumed that PTH enhanced the differentia-
tion of osteoblast progenitor cells (Ob_pro), but inhibited the 
differentiation of osteoblasts precursor cells into Ob_m (34). 
On the other hand, Lemaire et  al. assumed that PTH binds to 
receptors on Ob_m, whereby it stimulates production of RANKL, 
but inhibits production of OPG (31). We based our model on 
some of the assumptions of earlier models, but we also included 
the dynamics of chemical species, including OPG, RANKL, PTH, 
Runx2, Sclerostin, TGF-β, and Wnt. In addition, we included 
explicit mechanisms to mimic loading and the circadian rhythm 
of PTH in our model. We used a modular approach for the model 
construction using the modeling standard, Systems Biology 
Markup Language (SBML) (41), which will allow for modifica-
tions and further extensions, as required.
MaTerials anD MeThODs
The model was based on a number of assumptions supported 
by the literature, but to avoid too much complexity at this stage 
of the model development, detail of some of the processes has 
been omitted. For example, we modeled mechanical loading 
by including a dummy species “LOAD,” which could be turned 
on and off during the simulation and simply assumed that 
osteocytes are activated in the presence of LOAD. This was rep-
resented by the reaction Ocy_I + LOAD → Ocy_A + LOAD, 
where Ocy_I and Ocy_A are the pools of inactive and active 
osteocytes, respectively. For most of the reactions, we used 
mass action kinetics. We also used Hill kinetics for some of the 
second-order reactions. For example, in reactions that represent 
binding of ligands to receptors, we assumed that the reaction 
would be limited by the number of receptors. This prevents 
activation of signaling pathways when ligands are present at 
low levels with an approximately linear increase in the rate 
for intermediate levels, which then reaches a maximum rate 
to represent saturation of the ligand. The model assumptions 
are given below.
The models were encoded in SBML (41), a modeling 
standard for biochemical networks, using the Python tool 
SBML shorthand (42). Model diagrams were constructed 
in CellDesigner (43) using the Systems Biology Graphical 
Notation (SBGN) (44) and deterministic simulations were car-
ried out in COPASI (45). Stochastic simulations were carried 
out on a cluster with our own simulator (gillespie2) (46), which 
is based on the Gillespie algorithm (47). The SBML code was 
deposited in the Biomodels database and assigned the identifier 
MODEL1602290000 (48). All graphs were constructed using 
the R package ggplot2 (49).
Model assumptions
The model was based on a number of assumptions that are given 
below. Each component (cell type or protein) in the model has a 
unique species ID and is shown in brackets if it differs from the 
component name.
Hematopoietic progenitor cells differentiate into osteoclast 
precursor cells (Ocl_p). This requires MCSF (3).
Osteoclast precursor cells differentiate into Ocl_m. This 
requires RANKL binding to Ocl_p (4). Precursor cells may 
undergo apoptosis.
Mature osteoclasts degrade bone, activate TGF-β (Tgfb_A), 
and undergo apoptosis.
Mesenchymal stem cells differentiate into Ob_pro. This 
requires active Wnt (Wnt_A) (50). MSCs also secrete MCSF (3) 
and RANKL (51).
Osteoblast progenitor cells differentiate into Ob_p. This 
requires active TGF-β (12). Ob_pro also secretes MCSF and 
RANKL (11).
Osteoblast precursor cells differentiate into Ob_m. Ob_p 
may secrete MCSF, OPG, and RANKL (11). Tgfb_A and PTH 
reversibly bind to Ob_p to inhibit differentiation of Ob_p into 
mature cells (12). Ob_m form new bone, secrete MCSF, OPG, 
and RANKL (11), mature into inactive osteocytes (Ocy_I), 
or undergo apoptosis. Maturation of Ob_m into osteocytes is 
enhanced by Tfgb_A (12, 52). Apoptosis of osteoblasts requires 
Bax and is inhibited by Bcl-2. We included this detail as it has 
been shown that PTH has antiapoptotic effects on osteoblasts 
via Runx2 and upregulation of Bcl-2 (21). As in previous 
models (32, 33), we assumed that OPG is mainly secreted by 
Ob_m and that RANKL is mainly secreted by Ob_p. However, 
model parameters can be changed to model other possibilities, 
if desired.
Inactive osteocytes are activated by loading (LOAD) or PTH 
to become activated (Ocy_A). Ocy_I also secretes Sost, which 
inhibits Wnt signaling. Ocy_I, but not Ocy_A, may undergo 
apoptosis (14).
Activated osteocytes do not secrete Sost and so indirectly 
increases Wnt activation (53). Activation of osteocytes is a 
dynamic process, and so, we also include inactivation of Ocy_A. 
Osteocytes secrete RANKL in either the active or inactive 
state (54).
Osteoprotegrin is a decoy receptor and reversibly binds to 
RANKL to inhibit its activity (8) We include degradation of 
OPG_RANKL as it has been shown that when OPG binds to 
RANKL they are internalized by an endocytosis pathway and 
then degraded (55).
We assume a low basal level of PTH, which leads to very low 
activation of signaling pathways and so include basal turnover. 
We also model the effect of the circadian rhythm of PTH by 
including two model events which simulate a peak of PTH in the 
late afternoon (5:00 p.m.) and second larger peak of PTH during 
the night (about 2:00 a.m.).
FigUre 1 | simplified network diagram of the model. Diagram showing the main components and interactions in the model. More detailed diagrams showing 
all the components of the model are shown in Figures 2–5.
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Parathyroid hormone reversibly binds to Ocy_I, which 
 suppresses the secretion of sclerostin (17) and RANKL by osteo-
cytes and inhibits apoptosis of osteocytes.
Parathyroid hormone binds to Ob_p to inhibit differentiation 
into Ob_m, and we assume that it increases the rate of RANKL 
secretion and decreases OPG secretion by precursor cells.
Parathyroid hormone binds to Ob_m, and we assume that 
Ob_m has a much stronger affinity for PTH than Ob_p or Ocy_I. 
PTH increases the secretion of RANKL and inhibits the secre-
tion of OPG by Ob_m (18). We assume that PTH has no effect 
on MCSF secretion by osteoblast cells. PTH activates Wnt and 
CREB when bound to Ob_m. Activated CREB reversibly binds 
to Runx2, which leads to synthesis of Bcl2 and inhibition of Bax 
(21). PTH also increases the degradation rate of Runx2 (21) and 
TGF-β (56). We assume that Ob_m bound by PTH may form new 
bone and undergo apoptosis.
TGF-β is secreted by Ob_m in an inactive state (Tgfb_I) and 
is activated by Ocl_m. Tgfb_A is required for differentiation of 
Ob_pro to Ob_p, but inhibits differentiation of Ob_p to Ob_m 
(12). Tgfb_A increases the rate of Ob_m maturation into Ocy_I 
(12, 52). It also increases the rate of RANKL secretion by Ob_p.
We also include Wnt activation by a PTH-independent 
mechanism and degradation reactions for all the protein species 
included in the model.
We assumed that mechanical loading occurs at set times 
for periods of about 30 min and varied the number of loading 
events per day to represent different levels of physical activity. 
In our model, loading represents physical exercise rather than 
the background loading that occurs throughout the day during 
everyday life (i.e., movement in general and short periods of 
walking and climbing stairs, etc.). We made this assumption, as 
vigorous physical activity is much more likely to be osteogenic 
(57). We assumed that bone mass is maintained by two bouts of 
loading per day and set these to occur at about 9:00 a.m. and 
4:30 p.m. in the simulations. We also examined the effects of 
three or four bouts of loading per day to represent the effects of 
increased physical activity, and just one bout of loading to repre-
sent a sedentary lifestyle. LOAD either takes the value 0 or 1. The 
reaction for osteocyte activation by loading (Ocy_I + LOAD → 
Ocy_A + LOAD) can only take place when LOAD = 1. We did 
not include direct effects of loading on osteoblasts or osteoclasts, 
but assumed that these cells were indirectly affected by loading 
via the effects on osteocytes. However, these could be added in a 
future development of the model if required.
We assumed that bone mass has an initial value of 2000 units 
and that each mature osteoblast/osteoclast can degrade/form 1 
unit of bone in each degradation/formation reaction, respec-
tively. We assumed that the ratio of active osteoblasts to active 
osteoclasts during bone remodeling is approximately 10:1 (39). 
About 10% of the skeleton is remodeled each year; however, it 
was only feasible to carry out simulations over 100-day periods 
due to the time required for stochastic simulation. Therefore, we 
increased the rate of bone turnover so that 10% of bone is remod-
eled in about 5 months under normal conditions. The half-life of 
osteoblasts and osteoclasts is about 12 and 8 days, respectively 
(58, 59). However, we have simplified the remodeling process 
and have not included spatial aspects and the time delay involved 
in movement of osteoblasts to the site of remodeling, but instead 
AB
FigUre 2 | network diagrams showing effects of loading and PTh on 
bone. (a) Activation of osteocytes and Wnt signaling by load; (B) effects of 
PTH on osteocytes and osteoblasts. Figures 2–5 were constructed in 
CellDesigner using the SBGN. See in Section “Materials and Methods,” 
modeling assumptions for further details.
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have assumed that Ob_m and osteoclasts are immediately active, 
participate in remodeling, and then undergo apoptosis (or in 
the case of osteoblasts mature to osteocytes). Therefore, it was 
necessary for the model that levels of Ob_m and osteoclasts have 
a half-life of about 1 day.
We mainly used deterministic simulation (LSODA algorithm 
in COPASI) as this is valid for a model in which bone remod-
eling takes place in a representative elementary volume of the 
tissue. However, stochastic effects may lead to heterogeneity 
in cellular responses, and so, we also explored this possibility. 
It should be noted that we used low molecular numbers in the 
models so that it was feasible to do stochastic simulation and, 
therefore, the model output should be viewed as qualitative 
rather than quantitative data. It would be possible to scale the 
model for larger numbers if required to give similar model 
behavior.
A simplified diagram showing the key components of the 
model is shown in Figure  1, and graphical network diagrams 
showing all the model species and reactions are shown in 
Figures  2–5. In addition, full details of the model species is 
given in Table 1, and further details of the reactions, parameters, 
events, sensitivity analysis, and parameter scans are included 
in the supplementary file (Tables S1–S5 in Supplementary 
Material). We also show simulation output for each subpart of 
the model over short timescales, so that the dynamics of the 
molecular interactions can be easily examined (Figures S1–S5 
in Supplementary Material).
resUlTs
Model Output shows that Maintenance 
of Bone Mass requires Both regular 
loading and a PTh circadian rhythm
The model output shows that bone mass is maintained by regular 
intermittent loading (two 30-min bouts per day) and a normal 
PTH circadian rhythm (two peaks per day) (Figure 6A). If load-
ing is reduced to one bout per day with a normal PTH circadian 
cycle, then bone mass gradually decreases with time (Figure 6B). 
If PTH only peaks once per day with two bouts of loading per 
day, bone mass also decreases by a similar amount (Figure 6C). 
Examination of the model output showed that, immediately after 
loading and/or increased levels of PTH, there was an overall 
increase in bone turnover due to an increase in both Ocl_m 
and osteoblasts. However, there was more bone formation due 
to a greater increase in osteoblasts and hence, an increase in the 
osteoblast/osteoclast ratio (Figure 7).
The absence of loading and/or a 
complete Disruption of the PTh circadian 
rhythm results in severe Bone loss
With aging, there is likely to be a decline in levels of physical 
activity and dysregulation of circadian cycles, including PTH, 
which will have major consequences for bone remodeling. Other 
possibilities are a complete absence of loading but with an intact 
PTH cycle, e.g., injury or sickness, leading to prolonged bed rest; 
or a disrupted PTH cycle but with normal loading, e.g., in disease 
such as hypoparathyroidism, or an elderly person who is very 
physically active. The model was simulated under four scenarios: 
a decline in loading (one event per day) and absence of the early 
evening PTH peak, no loading with an intact PTH circadian 
rhythm, normal loading but a totally disrupted PTH cycle (no 
peaks), and no loading and a totally disrupted PTH cycle. The 
model output shows that all four scenarios lead to a loss of bone 
mass over time (Table  2, Figure  6D). A reduction in loading 
leads to a greater bone loss due to a decrease in the osteoblast/
osteoclast ratio. Also, of note, when there is no loading or PTH 
peaks, there is very little bone remodeling, as seen by the low 
levels of osteoblasts and osteoclasts (Table 2). This is due to high 
levels of Sost, which inhibits Wnt signaling, an increase in the 
RANKL/OPG ratio, and high levels of Bax (Figure 8). This would 
suggest that, although there is no greater loss in bone mass in the 
AB
FigUre 3 | network diagram showing species and reactions involved in osteoblast and osteoclast differentiation (a) Osteoblast differentiation; 
(B) osteoclast differentiation. See in Section “Materials and Methods,” modeling assumptions for further details.
A
B
FigUre 4 | network diagram showing species and reactions affected 
by TgF-β and bone turnover. (a) TGF-β is secreted by osteoblasts, 
activated by osteoclasts and affects osteoblast differentiation. PTH also 
enhances degradation of TGF-β; (B) bone is formed by osteoblasts and 
degraded by osteoclasts. See in Section “Materials and Methods,” modeling 
assumptions for further details.
FigUre 5 | network diagram showing secretion of molecules. 
Thickness of lines indicates relative rates of secretion by different bone 
types. See Section “Materials and Methods,” modeling assumptions for 
further details.
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complete absence of physical activity or intermittent PTH peaks, 
the remaining bone is likely to contain more micro-fractures 
leading to a greater risk of fracture.
loading and PTh Maintain Bone Mass via 
increased Wnt signaling, a Decrease in 
ranKl/OPg ratio and a Decrease in 
Osteoblast apoptosis
As signaling takes place over short timescale, we also ran simula-
tions over 10-day periods, so that it is easier to distinguish the 
TaBle 1 | list of model species.
species Description Database  
term
initial 
amount
Bone Bone mass 2000
HSC Hematopoietic stem cell CL:1001610 100
MSC Mesenchymal stem cell CL:0000134 100
Ob_pro Osteoblast progenitor CL:0001040 0
Ob_p Osteoblast precursor CL:0007010 0
Ob_m Mature osteoblast CL:0001039 0
Ocl_p Osteoclast precursor CL:0000778 0
Ocl_m Mature osteoclast CL:0000779 0
Ocy_I Inactive osteocyte CL:0000137 1800
Ocy_A Active osteocyte CL:0000137 0
Ob_p_PTH Ob precursor bound by PTH 0
Ob_p_
Tgfb_A
Ob precursor bound by Tgfβ 0
Ob_m_PTH Ob_m bound by PTH 0
Ocl_p_
RANKL
Ocl_p bound by RANKL 0
Ocy_I_PTH Ocy_I bound by PTH 0
Bax Proapoptotic protein Q07812 100
Bcl2 Antiapoptotic protein P10415 0
Bax_Bcl2 Bax/Bcl2 complex (inhibits Bax) 0
CREB Cyclic AMP-responsive element-
binding protein 1
P16220 100
CREB_P Phosphorylated CREB 0
CREB_
Runx2
CREB/Runx2 complex 0
MCSF Macrophage colony-stimulating 
factor 1
P09603 5
RANKL RANK ligand O14788 0
OPG Osteoprotegerin O00300 0
OPG_
RANKL
RANKL bound to OPG 0
PTH Parathyroid hormone P01270 10 or 
170
Runx2 Runt-related transcription factor 2 Q13950 10
Tgfb_A Active transforming growth factor 
beta-1
P01137 5
Tgfb_I Inactive Tgfβ P01137 500
Wnt_A Activated Wnt P04628 0
Wnt_I Inactive Wnt 200
Sost Sclerostin Q9BQB4 0
LOAD Mechanical stimulation 0
X Dummy species for timing events 0
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different patterns in Wnt activation between the different models 
(Figures  9A,B). After each loading or PTH event, there is an 
increase in osteocyte activity so that Sost levels decline and Wnt 
signaling increases (Figure 9A); with only one loading event per 
day and only one PTH peak per day, Wnt signaling is reduced 
(Figure  9B). The increase in Wnt signaling accounts for the 
increase in osteoblast differentiation (Figure 6A). To examine the 
relative effects of loading and PTH on Wnt signaling, we exam-
ined levels of Sost and Wnt when either just loading was reduced 
or just PTH was reduced. In both cases, there was a similar reduc-
tion in Wnt activation (Figures 10A,B). Loading and PTH also 
led to an increase in both OPG and RANKL, with a decrease in 
the RANKL/OPG ratio (Figures 9C,D). A reduction in loading 
only or a reduction in PTH only led to a similar increase in the 
RANKL/OPG ratio (Figures 10C,D), but the effects were due to 
different pathways, as there was a synergistic effect when both 
loading and PTH were reduced (Figure 9D).
In order to examine the effects of loading and PTH on levels of 
Bax, it was also more informative to look at output from simula-
tions on short timescales as the effects were transient. It can be 
seen that Bax levels fluctuate, and the minima correspond to 
the times that PTH levels peak. When there is a normal PTH 
circadian rhythm, loading does not have much effect on levels of 
Bax (compare Figure 9E with Figure 10E). However, when there 
is only one PTH peak per day, additional loading reduces levels 
of Bax (compare Figure 9F with Figure 10F). Therefore, there is 
a transient decline in osteoblast apoptosis after each PTH event, 
which may be exacerbated by loading. Although, loading did not 
directly affect Bax, the effects were mediated via an increase in the 
number of osteoblasts due to increased Wnt signaling. This led 
to more PTH binding to osteoblasts to enhance Runx2 signaling 
and synthesis of Bcl2, which bound to Bax to inhibit its activity.
simulation of interventions suggests 
Treatments to Prevent Bone loss in aging
To simulate interventions, we used the model with one loading 
event and one PTH peak per day, as this model mimics the 
situation in aging with reduced physical activity and a disrupted 
PTH circadian rhythm with a significant loss of bone mass over 
a 100-day period.
simulation of ranKl inhibition
The RANKL inhibitor, denosumab has recently been introduced 
as a new treatment for osteoporosis and has been shown to 
increase bone mass in postmenopausal women (60). In order to 
simulate the effects of RANKL inhibition, we decreased the value 
of the parameter that controls the rate of RANKL binding to its 
receptor on osteoclasts (kbinOclpRankl) from 0.001 to 0.0001 in steps 
of 0.0001. This led to a gradual increase in bone mass, and at the 
lowest value, bone mass increased to just above its normal value 
(Figure 11A).
simulation of sost inhibition
Sost inhibitors are currently being tested as potential treatments 
for osteoporosis and show promise as an anabolic agent (61). 
To simulate the inhibition of Sost, we increased the value of the 
degradation rate of Sost (kdegSost) from its default value of 0.004 to 
0.04, in steps of 0.004. This led to a rapid increase in bone mass 
as kdegSost initially increased and then flattened off, suggesting a 
maximal effect for this intervention (Figure 11B).
simulation of PTh injections
The anabolic effect of daily PTH injections has been well docu-
mented, but the effects of PTH on bone metabolism are complex 
and the underlying mechanisms are not well understood (62). 
We simulated the effect of giving one, two, or three PTH injec-
tions per day. In the case of one injection, this was simulated to 
occur in the late afternoon (at the time that PTH would normally 
peak). One injection was insufficient to restore bone mass even 
if we increased the amount of the PTH peak (Figure  11C). 
However, an additional injection was able to restore bone mass if 
the injected amount of PTH was set to 200, and with three injec-
tions, a low dose was sufficient (Figure 11C).
FigUre 6 | effect of loading and an intact PTh circadian rhythm on bone homeostasis. (a) Model output shows that two loading events per day and an 
intact circadian rhythm of PTH with two peaks per day leads to maintenance of bone mass; (B) a decrease in loading (one event per day) with two PTH peaks per 
day leads to a decline in bone mass with time; (c) a decrease in PTH (only one peak per day) with two loading events leads to decline in bone mass with time; and 
(D) a decrease in both loading and PTH (one loading event and one PTH peak per day) leads to a greater decline in bone mass. 
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simulation of continuous PTh
It has been shown that administration of PTH by pump deliv-
ery can increase bone mass in children suffering from severe 
hypoparathyroidism (63), but many studies show that continu-
ous administration of PTH can lead to bone loss, e.g., Ref. (26). 
Therefore, we ran simulations to see if our model could capture 
this behavior by increasing the value of ksynPTH, which had the effect 
of increasing the basal levels of PTH. As observed experimentally, 
our model predicted that there is an optimal level of PTH with 
either low levels or continuous high levels being detrimental 
(Figure 11D).
simulation of effects of Bisphosphonates
Bisphosphonates inhibit the degradation of bone by increasing 
the rate of osteoclast apoptosis or inhibiting osteoclast differ-
entiation (64) and are the most used drug for the treatment of 
osteoporosis in the UK. We simulated the effect of administering 
bisphosphonates at increasing doses by increasing the rate of 
osteoclast apoptosis (kdeathOcl) from 6.5e−5 to 1.3e−4 (Figure 11E). 
This led to an increase in bone mass with no maximal effect being 
apparent.
simulation of effect of additional loading
It is known that physical activity is important for maintaining 
bone mass. We used the model to investigate the effect of differ-
ent loading regimes with zero, one, two, or three loads per day 
using the model with only one PTH peak per day (at 0200 hours). 
With only one PTH peak per day, it was necessary to have three 
loading events per day (Figure  11F). Interestingly, the timing 
of the additional loads was found to be important (as shown by 
the range of values in Figure 11F), and the model showed that 
the best time for a single load was 2100  hours (Figure  12A). 
Since physical activity close to bedtime may have undesirable 
effects, we chose 1848 hours for the first load (i.e., the time that 
FigUre 7 | simulations over 10-day periods to show effect of loading and PTh events on osteoblast and osteoclast numbers. (a) Model with two 
loading events and two PTH peaks per day; (B) one loading event and two PTH peaks per day; (c) two loading events and one PTH peak per day; (D) one loading 
event and one PTH peak per day. Osteoblast levels peak after each loading or PTH event, and so reducing the number of either loading events (B) or PTH events 
(c) reduces the frequency and maximum level of the osteoblast peaks. Reducing both loading and PTH (D) further reduces the frequency of osteoblast peaks.
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gave maximum benefit if night time loading is excluded), when 
investigating the best time for the second load (Figure  12B). 
An additional load was least effective if administered close to 
1900 or 0200 hours, when loading and PTH peaks were already 
present (Figure  11F), and the model predicted that the best 
time for the second loading event was early afternoon or very 
late evening (Figure  12B). The time of the second load was 
then fixed at 1400  hours, and the time for the third load was 
varied. Provided the third load was not close to another loading 
event, bone mass increased above basal level over a 100-day time 
period, with maximum benefit occurring if the loading events 
were about 4–5 h apart (Figure 12C).
sensitivity analysis shows that Bone 
remodeling is Mainly affected by 
components of the Wnt and PTh Pathways
Sensitivity analysis was carried out in COPASI on the deter-
ministic version of the model with two loading and two peaks 
of PTH per day, in which bone homeostasis is maintained. The 
results are shown in File S2 in Supplementary Material. The 
parameters which affected the final level of bone mass after 
100-day simulation are highlighted (green for an increase and 
red for a decrease in bone mass) and summarized in Table S4 in 
Supplementary Material of File S1 in Supplementary Material. 
The sensitive parameters include those involved in osteoblast 
differentiation (kdiffMSC and kdiffObp), osteoclast differentiation 
(e.g., kdiffHSC, kdegMCSF, and ksecRANKLbyOcy), the Wnt pathway 
(e.g., kactWnt, kdegSost, and ksecSost), the PTH pathway especially the 
effects of PTH on osteoblast apoptosis (e.g., kbinCrebRunx2, ksynBcl2, 
and kdeathOb), and those that affected the RANKL/OPG ratio 
(e.g., ksecOPGbyObm, kinhibRANKL, and ksecRANKLbyOcy). These parameters 
were then varied in the range of 0.5–2 times their default 
values, and the model simulated to examine the effect on 
all the model components. A summary showing the effects 
of changing the sensitive parameters on bone mass, Ob_m, 
Ocl_m, and Ocy_A is shown in Table S5 in Supplementary 
Material.
FigUre 8 | Model output when there is no loading and no PTh peaks. (a) Bone mass declines steadily with age and there is very little bone turnover as 
shown by low levels of osteoblasts and osteoclasts; (B) Sost levels remain high and so Wnt is mainly inactive; (c) RANKL and OPG levels are both lower, but with 
an overall increase in the RANKL/OPG ratio; (D) Bax levels remain high indicating that osteoblast apoptosis is high under these conditions.
TaBle 2 | effect of reducing load and/or PTh on bone turnover.
LOAD (number of events per day) 1 0 2 0
PTH (number of peaks per day) 1 2 0 0
Mature osteoblasts (mean level) 73.8 47.9 102.0 15.3
Mature osteoclasts (mean level) 21.8 14.9 27.1 6.6
Osteoblast/osteoclast ratio 3.39 3.21 3.76 2.32
Bone mass at day 100 1714.1 1722.6 1821.5 1724.3
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stochastic Model indicates that Variability 
in Bax levels May lead to heterogeneity 
in cellular responses
We also ran all the models with a stochastic algorithm (Gillespie 
direct method) to investigate whether stochastic effects are 
important in bone remodeling. Overall the results were very simi-
lar to the deterministic output (compare Figure 13 to Figure 6). 
However, it can be seen from the SD of 100 simulations that there 
is variability in the amount of bone mass at day 100. We also noted 
that intermittent PTH peaks affected the variability of Bax levels 
with Bax being more variable and lower for longer periods of 
time, when PTH peaks are present (Figure 14). So when PTH 
peaks, Bax levels decline, and so, there is a delay in osteoblast 
apoptosis. There is variability in both the minimum level of Bax 
and the length of time that it is below a threshold required for 
apoptosis between simulations, and so there will be variability in 
the lifespan of mature osteoblasts.
DiscUssiOn
We have used computational modeling to examine some of 
the key processes involved in bone remodeling. We included 
the differentiation of osteoblasts and osteoclasts and the major 
signaling pathways involved in these processes. We also included 
osteocytes as they respond to mechanical stimuli and secrete 
signaling molecules, which are important in bone remodeling. 
We assumed that PTH is normally present in the extracellular 
environment at low basal levels, which are below the threshold 
required for cell signaling, but that it is has a circadian rhythm, 
whereby it peaks twice a day. The main purpose of the model was 
to examine the effects of loading and the PTH circadian rhythm 
FigUre 9 | Model output showing effects of reduced loading and a disruption in the PTh circadian on signaling pathways over 10-day time period. 
Comparison of model with two loading events and two PTH peaks per day (a,c,e) and model with one loading event and one PTH peak per day (B,D,F) show that 
reduced loading and PTH leads to (a,B) higher Sost levels and less activated Wnt; (c,D) less OPG and, therefore, a higher RANKL/OPG ratio; and (e,F) less Runx2 
activity and higher levels of Bax.
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on bone homeostasis and to provide a basic model, which we 
can extend in the future to examine the effects of loading and 
PTH in more detail in combination with other signaling path-
ways, so that it can be used to examine possible new therapeutic 
interventions or combinations of therapies. In addition, we tested 
whether our model would predict opposing effects of continuous 
or intermittent PTH treatments on bone remodeling as has been 
previously shown experimentally and in previous mathematical 
models.
The model parameters for bone turnover were adjusted so 
that bone mass is maintained over time with two loading events 
and an intact PTH circadian rhythm with two peaks per day, 
FigUre 10 | Model output showing effects of either reduced loading or a disruption in the PTh circadian on signaling pathways over 10-day time 
period. Comparison of model with one loading event and two PTH peaks per day (a,c,e) and model with two loading events and one PTH peak per day 
(B,D,F) show that reduced loading leads to (a,B) less Wnt activation compared to reduced PTH; (c,D) less OPG and, therefore, a higher RANKL/OPG ratio; 
(e,F) but reducing PTH leads to less Runx2 activity and higher levels of Bax.
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although there were fluctuations in bone mass over the time 
course due to bone remodeling taking place. Either a decline 
in loading (one event per day) or disruption to the PTH cycle 
(just one peak per day) led to bone mass gradually declining 
with time. Examination of the model output showed that this 
was mainly due to higher levels of sclerostin and inhibition of 
Wnt signaling, as has been shown experimentally (65). Loading 
and PTH also increased the levels of OPG so that the RANKL/
OPG ratio decreased leading to an increase in the ratio of Ob_m 
to Ocl_m, and hence, more bone formation took place after 
FigUre 11 | Model output showing effect of simulated interventions on bone remodeling. The deterministic model of “simulated aging” (one loading event 
and one PTH peak per day) was used to simulate interventions and the bone mass on day 100 was recorded to see which interventions could restore the loss of 
bone mass (i.e., a bone mass of 1714) to “normal” levels (i.e., 2000, indicated by horizontal line in each graph). (a) RANKL inhibition was simulated by decreasing 
the binding rate of RANKL to osteoclasts from 0.001 to 0.0001; (B) Sost inhibition was simulated by increasing the rate of Sost degradation from 0.004 to 0.04; 
(c) PTH injections were simulated by including additional events in the model, and different doses were simulated by varying the value of the PTH peak at the event; 
(D) continuous PTH administration was simulated by increasing the rate of PTH synthesis from 0.02 to 0.2; (e) bisphosphonate treatment was simulated by 
increasing the rate of osteoclast apoptosis; (F) increased physical activity was simulated by including additional events for loading, the effect depended on the timing 
of the loading events and vertical lines show the range of values obtained.
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FigUre 12 | effect of timing of loading events on bone mass. 
(Continued)
FigUre 12 | continued
(a) Model with one PTH peak and one loading event per day shows that best 
time for loading is in the late evening; (B) model with one PTH peak per day 
and one loading event set at 1900 hours, shows that best time for second 
loading event is at 1400 hours (excluding peak at about 0100 hours); 
(c) model with one PTH peak and two loading events per day (at 1400 and 
1900 hours) shows that a third loading event leads to an increase bone mass 
if it is not close to another loading event. Vertical dashed line shows time of 
PTH peak, vertical dotted line shows time of loading event(s), solid horizontal 
line indicates normal bone mass.
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each loading or PTH event. As expected, after each PTH event, 
there was an increase in Runx2 activity leading to temporary 
decline in Bax and, therefore, less osteoblast apoptosis for short 
periods. This was also the case after each loading event due to the 
increase levels of Ob_m and more PTH binding to osteoblasts 
to initiate Runx2 signaling. Loading also led to slightly higher 
levels of PTH due to a decrease in PTH degradation, since 
degradation only takes place once PTH has been internalized. 
We modeled this by assuming that PTH is released from the 
osteoblast and then degraded, but a future modification of the 
model could include PTH receptors so that receptor-bound PTH 
is internalized.
We carried out a sensitivity analysis to investigate which 
model parameters had positive or negative effects on bone 
mass, as this would not only confirm that the expected behavior 
based on prior knowledge of bone remodeling but would also 
suggest potential targets for interventions. The most sensitive 
parameters were those that affected the lifespan of osteoblasts 
or osteoclasts and the differentiation process for both bone 
cells. Parameters involving all the signaling pathways included 
in the model were also important with no particular pathway 
being dominant. Therefore, our model suggests that interven-
tions involving multiple targets may be more effective than 
a single target. This would require further investigation, and 
computational models will be invaluable in the future to help 
suggest which combination of targets would be appropriate for 
experimental testing.
Our model (in which there was only one loading event and 
PTH peak per day) reproduced the effects of continuous versus 
intermittent PTH, with the former intervention leading to bone 
loss if the concentration of PTH is high, and the latter able to 
maintain bone mass if administered twice daily. Continuous 
PTH at intermediate levels was able to maintain bone mass. This 
was due to an increase in Wnt signaling. However, high levels of 
continuous PTH led to loss of bone mass, as continuous PTH 
both reduced Runx2 activity leading to an increase in osteoblast 
apoptosis and increasedthe RANKL/OPG ratio leading to an 
increase in osteoclast differentiation. On the other hand, the 
model showed that intermittent PTH maintained bone mass 
due to increased Wnt signaling and the activation of CREB and 
Runx2, which led to temporary decline in osteoblast apoptosis 
after each simulated “injection.” The temporary effects of PTH on 
osteoblast apoptosis was due to the fact that PTH also enhanced 
the degradation of Runx2 to provide a negative feedback loop 
to terminate signaling. The complex effects of PTH means that 
using treatments, such as teriparatide, require caution, as is 
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FigUre 13 | continued
already known (66). Our  model suggests that whether or not 
the patient has an impaired PTH circadian rhythm should also 
be investigated in order to avoid increasing bone loss or at the 
other extreme to increase the risk of bone tumors. For example, 
it has been shown that the timing of teriparatide injections is 
important in postmenopausal osteoporosis with regards to the 
natural circadian rhythm of bone resorption and effectiveness of 
treatment (67, 68).
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FigUre 13 | stochastic model shows similar behavior to the deterministic models. (a,B) Model with two loading events and two PTH peaks per day; 
(c,D) model with one loading event and two PTH peaks per day; (e,F) model with two loading events and one PTH peak per day; (g,h) model with one loading 
event and one PTH peak per day. Output from the stochastic model shows similar behavior to the deterministic model (Figure 6). (a,c,e,F) show output from one 
individual stochastic simulation; (B,D,F,h) show the mean levels (dark curves) and ±1.96 SDs from the mean (light shaded region) from 100 individual simulations.
In addition to PTH treatments, we modeled the effects of 
other interventions, which are currently in use or being tested 
as a potential treatment for osteoporosis. Our model was able 
to reproduce the effects of RANKL inhibitors, Sost inhibitors, 
and bisphosphonates. We also examined the effects of increased 
physical activity by varying the number of loading events per 
day. Interestingly, our model predicted that the timing of physical 
activity may be important. This is mainly due to the natural 
circadian rhythm of PTH and also the fact that both PTH and 
loading lead to transitory signaling due to negative feedback 
loops within signaling pathways. Therefore, short, regular 
intervals of activity may be more beneficial than one prolonged 
exercise period per day. In addition, the benefits of exercise may 
be more pronounced if taken at times when PTH levels are 
normally low. It would be interesting to test these predictions in 
a clinical setting or an animal model of osteoporosis.
We modeled the effect of loading by simply assuming that 
load activates osteocytes, which in turn activates Wnt signal-
ing and osteoblast differentiation. It is known that purinergic 
signaling also plays an important role in bone remodeling 
and that both osteoblasts and osteoclasts express P2 receptors 
(23). It is also known that osteocytes, osteoblasts, and osteo-
clasts secrete ATP in response to loading (69–71). Therefore, 
a proposed extension to this model is to include the direct 
effects of loading on all bone cells. Interestingly, the model 
predicted that timing of the loading events was important 
for maintenance of bone mass and suggested that spacing 
the loads throughout the day and at times that are not close 
to the natural peaks of the PTH circadian rhythm is more 
beneficial. It would be interesting to test this experimentally 
by having groups of subjects undergoing different amounts of 
physical activity using different time schedules. The interaction 
between physical activity and the PTH circadian rhythm also 
warrants further study. It also raises the question of whether 
shift workers and persons who make frequent long haul flights 
have an accelerated loss of bone mass with age and so are 
more at risk of osteoporosis. Lastly, the model suggests that a 
combination of increased physical activity and daily low dose 
PTH injections may be beneficial.
We modeled the process of bone remodeling over fairly 
short timescales (100 days) as in previous mathematical models. 
However, the models could be modified so that they could be 
run over longer timescales in order to examine changes that take 
place during aging. For example, it has been shown that levels of 
PTH have a circadian rhythm, which changes with age (27) and, 
therefore, it would be interesting to include this aspect of PTH 
regulation. Other molecular pathways are also known to change 
with age, such as TGF-β signaling (72) and the OPG/RANKL 
pathway (73). It is known that stem cells change with age, and so, 
the model could be used to examine the effects of damage to stem 
cells on the differentiation processes of osteoblasts and osteoclasts 
(74, 75). Lastly, the model could be modified to include the effects 
of different loading regimes, e.g., repetitive and/or damaging by 
adding reactions to represent damage to bone cells and including 
different types of loading. Cellular responses to mechanical signals 
also change with age (76), which may be due to dysregulation of 
signaling pathways with age. In conclusion, our computer model 
demonstrates the utility of a computational tool to investigate 
how age-related changes affect bone remodeling to complement 
experimental approaches. We have shown how modeling can be 
used to test possible interventions or combinations of therapies 
that could prevent or slow down the loss of bone mass with age, 
and to suggest future studies. In particular, our model suggests 
that the relationship between mechanical stimulation and the 
PTH circadian with implications for the timing of interventions 
requires further investigation.
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